Back to Search
MARISOL PENICHET, M.D.
M.D.
Anatomic Pathology & Clinical Pathology Physician
NPI: 1639365133IndividualAccepts Medicare
Specialties, Licenses & Credentials
Anatomic Pathology & Clinical Pathology PhysicianPrimary
Pathology — Anatomic Pathology & Clinical Pathology
Code: 207ZP0102X
A84142(CA)
CMS Specialties
PrimaryPATHOLOGY
Education
OTHER
Class of 1990
Research & Publications (20)
A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.
PMID 11455061·Hum Antibodies·2001
7-preclinical
A murine B cell lymphoma expressing human HER2 / neu undergoes spontaneous tumor regression and elicits antitumor immunity.
PMID 11258791·Cancer Immunol Immunother·2001
4-observational
Antibody-cytokine fusion proteins for the therapy of cancer.
PMID 11223071·J Immunol Methods·2001
6-review
A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome.
PMID 19215191·Hum Gene Ther·2009
7-preclinical
Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species.
PMID 18946492·Leukemia·2009
8-other
Recombinant polymeric IgG anti-Rh: a novel strategy for development of direct agglutinating reagents.
PMID 18848836·J Immunol Methods·2009
7-preclinical
Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.
PMID 18941743·Cancer Immunol Immunother·2009
8-other
Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer.
PMID 19531256·Breast Cancer Res·2009
7-preclinical
A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide.
PMID 19455593·J Gene Med·2009
8-other
Antigen-induced immunomodulation in the pathogenesis of atherosclerosis.
PMID 18551190·Clin Dev Immunol·2008
6-review
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
PMID 18424742·J Immunol·2008
8-other
Antibody-cytokine fusion proteins: applications in cancer therapy.
PMID 18407765·Expert Opin Biol Ther·2008
6-review
A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model.
PMID 18347157·Mol Cancer Ther·2008
7-preclinical
Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells.
PMID 18025284·Mol Cancer Ther·2007
8-other
Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor.
PMID 17884229·J Control Release·2007
7-preclinical
Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid).
PMID 17630012·J Control Release·2007
7-preclinical
Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies.
PMID 17310381·Cancer Immunol Immunother·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2208 W 7TH ST
LOS ANGELES, CA 90057 - Phone
- (213) 384-3434
Quick Facts
- NPI
- 1639365133
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 36
- Publications
- 20
Are you this provider?
Claim Your Profile